No one follows PTX and that's precisely why I like this stock. MC of 11 mil is far below any sane valuation. Plenty of cash in the bank, strong pipeline. Only issue is the sector, way too many specie bio's are coming in with bad results and as a result the market is losing interest. Time will tell, but the diseases PTX are looking to treat could easily give this one a 200+ mil MC. I'd expect with some good results in the next 2 years we may see $1-$2. In happy with the risk here.
Ann: Paul Hopper moves to Non-Executive Director, page-3
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
